CANADIAN LITTLE LEAGUERS MAKE A DIFFERENCE IN A BIG WAY

Toronto, Canada - February 28, 2012 – Mark Lievonen, President of Sanofi Pasteur Limited, wishes to congratulate players of the Langley British Columbia Little League baseball team and their families and supporters for the initiative and success of the Canada-Uganda Pearl of Africa Baseball series. 

“This was more than just a baseball game,” says Mr. Lievonen. “This was a small group of Canadians who made a difference in a very big way."

Seven months ago, it was announced that the first African team ever to qualify for the Little League World Series would not have the chance to compete. Many players’ visa applications for travel to the United States were denied because their birth certificates were unavailable, a common situation in a country where many people are not born in hospitals. Uganda was scheduled to play Canada in August in Pennsylvania.

When British Columbia resident Ruth Hoffman read about the Ugandan team’s disappointment, she felt it was a great injustice. “These young players had worked and trained very hard to earn their spot in the World Series, and I was shocked to see that they were denied this once-in-a-lifetime opportunity,” she says.  She put her disappointment into action and quickly teamed up with Right To Play, a non-profit organization dedicated to improving the lives of children in some of the world’s poorest areas through the power of sport and play. 

With support from Right To Play and many donors and sponsors, they helped the Canadian team raise the funds needed to cover the cost of sending them to Africa so they could play the game they were meant to play. In fact, they did so well that they also raised enough money to contribute to other initiatives that will benefit the Ugandan players for years to come.

“We’re really proud that Sanofi Pasteur played a role in this extraordinary mission,” explains Mr. Lievonen. The company donated the various vaccines needed by the team to travel overseas, protecting the young players from meningococcal disease, hepatitis A and yellow fever. “We’re also very thankful to our partner, the International Travel Health and Vaccination Clinic in Langley BC, which administered the immunizations.”

“The Ugandan team ended up winning the historic game in Nakirebe 2 to 1, but it’s fair to say that everyone involved came away with a new sense of pride and accomplishment—and this is what team spirit is all about!” concludes Mr. Lievonen.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us
 
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.


Contacts:

Canadian Media Relations     
Nancy Simpson   
T. 416-667-2955
Nancy.simpson@sanofipasteur.com   
www.sanofipasteur.ca